TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky October Dexcom's (DXCM) solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook. But analysts remained upbeat even as Dexcom stock tumbled. During the calls with analysts, the diabetes devices maker said it expects the top end of their initial revenue guidance range to fall slightly below Wall Street's expectations, Leerink Partners analyst Mike Kratky said in a report. He sees 11% to 13% sales growth as being ...